IPM chemotherapy in cytokine refractory renal cell cancer

British Journal of Cancer

Volumn 88, Issue 10, 2003, Pages 1516-1521

  Shamash, J ^a   Steele, J P ^a   Wilson, P ^a   Nystrom, M ^a   Ansell, W ^a   Oliver, R T D ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Cisplatin; Irinotecan; Mitomycin; Renal cell carcinoma (RCC)

Indexed keywords

CISPLATIN; CYTOKINE; DEXAMETHASONE; FLUOROURACIL; FUROSEMIDE; GRANISETRON; INTERFERON; INTERLEUKIN 2; IRINOTECAN; MITOMYCIN C; SODIUM CHLORIDE;

ANOREXIA; ARTICLE; BLOOD TOXICITY; BRONCHOPNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG FATALITY; DRUG RESPONSE; DYSPNEA; HUMAN; INFECTION; KIDNEY CARCINOMA; MALAISE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, RENAL CELL; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; SURVIVAL; TREATMENT OUTCOME;

EID: 0038793710     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600934     Document Type: Article

References (18)

1. Allen MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore ME (2000) Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 83: 980-985
2. Anonymous (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators [see comments]. Lancet 353: 14-17
3. Atzpodien J, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M (2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trials. Br J Cancer 8: 1130-1136
4. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319-323
5. Childs R, Chernoff A, Contentin N (2000) Regression of metastatic renal cell carcinoma after nonmyeloablative allogenic peripheral blood stem cell transplantation. N Engl J Med 343: 750-758
6. Eton O, Legha SS, Bedikian AY et al (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20(8): 2045-2052
7. Gil-Delgado MA, Antoine EC, Guinet F, Bassot V, Grapin JP, Benhammonda A, Adam R, Castaing D, Bismuth H, Khayat D (2001) Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer. Am J Clin Oncol 24: 251-254
8. Janik JE, Sznol M, Urba WJ, Figlin R, Bukowski RM, Fyfe G, Pierce WC, Belldegrun A, Sharfman WH, Smith JWD 2nd et al (1993) Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer 72: 2656-2659
9. Ljungberg B, Rasmuson T, Grankvist K (1992) Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol 21: 160-163
10. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylyester R (2001) Radical nephrectomy plus interfereon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966-970
11. Miki T, Nonomura N, Takaha N, Nishimura K, Kojima Y, Sawada M, Okuyama A (1998) Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice. Int J Urol 5: 370-373
12. Negrier S, Escudier B, Lasset C (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338: 1272-1278
13. Oliver RTD, Miller RM, Mehta A, Barnett MJ (1988) A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol Biother 1: 14-20
14. Reese DM, Corry M, Small EJ (2000) Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. Cancer 88: 1310-1316
15. Rini BV, Durras M (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metasatic renal carcinoma. J Clin Oncol 18: 2419-2426
16. Shamash J, Slater S, Steele J, Tischowitz M, Farrugia D, Wilson P, Gallagher C, Oliver R, Rudd R, Slevin M (2000) IPM: a new outpatient schedule of irinotecan, cisplatin and mitomycin for the treatment of solid tumours. Br J Cancer 83 (suppl): (Abst: 4.9)
17. Stebbing JBC, Eisen T, Pyle L, Smalley K, Bridle H, Mar I, Capunar F, Ahern R, Gore ME (2001) The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 7: 953-958
18. Tobe SW, Noble-Topham SE, Andrulis IL, Hartwick RW, Skorecki KL, Warner E (1995) Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res 1: 1611-1615